Back to Results
First PageMeta Content
Pulmonary hypertension / Medicine / Pulmonary Hypertension Association / Heart failure / Ontario Ombudsman / Health / Hypertension / Anatomy


Ombudsman investigates cut in funds for rare-disease drugs Advocate is examining Ontario decision affecting therapy for fatal lung ailment JESSICA LEEDER 986 Words Tuesday, November 3, 2009 Page A9
Add to Reading List

Document Date: 2010-05-26 00:50:51

Open Document

File Size: 45,25 KB

Share Result on Facebook

City

Toronto / /

Company

Pfizer / CTVglobemedia Publishing Inc. / /

Country

Canada / /

IndustryTerm

pharmaceutical / /

MedicalCondition

pulmonary arteries / fatal pulmonary arterial hypertension / right-heart failure / abnormally high blood pressure / cancer / disease / Pulmonary arterial hypertension / shock / rare disease / colon cancer / cut / illness / rare lung disease / asthma / /

MedicalTreatment

combination drug therapy / lung transplant / /

Organization

Pulmonary Hypertension Association of Canada / Toronto hospital / Ministry of Health / /

Person

Phillip Crawley / Deb Matthews / Kathy Ilano / Clive Davis / Cindy Waters-Goodman / Darren Bell / JESSICA LEEDER / Bonnie Cameron / /

Position

deputy minister / office investigator / minister / rare-disease drugs Advocate / spokesman for Deb Matthews / Minister of Health / head / spokeswoman / /

Product

Flolan / Avastin / /

ProvinceOrState

Ontario / /

PublishedMedium

The Globe and Mail / /

SocialTag